PHILADELPHIA--Cleft lip and palate (CL/P) is the second most common birth defect in the world, affecting 1 in 700 live born babies. While the exact cause of CL/P is not well understood, investigators think it could be the result of a combination of genetics and environment. Cleft lip and palate are splits in the upper lip, the roof of the mouth, or both. This happens when cells in a baby's face and mouth don't fuse properly during early development. The result of a partial fusion, or no fusion at all, leaves a cleft.
In a new study published today in Science Advances, researchers from the Perelman School of Medicine at the University of Pennsylvania found more than 100 new genes that could lead to the development of CL/P. The team discovered that genetic variants near these genes are in regions of the genome called "enhancers," which regulate expression of genes to maintain proper cell identity.
Enrique Lin-Shiao, a doctoral student in the lab of Shelley L. Berger, PhD, the Daniel S. Och University Professor and director of the Penn Epigenetics Institute, described the role of the protein p63 in modulating expression of genes involved in craniofacial development. The transcription factor p63 guides other molecules to open or close DNA structures in the nucleus called chromatin. This duty of p63 helps enhancers do their job of allowing genes to be expressed into mRNA, or not. Mutations in human p63 lead to an array of developmental defects, including clefting. Knowledge is limited about p63's role in human craniofacial development due in part to a lack of comparable animal models. However, now it is known that p63 binds to and remodels chromatin to coordinate enhancers associated with epithelial cells that are important for the fusion of the palate during development.
"We combined our molecular findings with genome data from colleagues at the University of Bonn who work with genetic data of patients with cleft palates or lips," said Lin-Shiao. "In the datasets, we found that many of the genes that are highly associated with clefting are located near the enhancer regions that work with p63. This gives us brand new insight into the mechanisms that could lead to disease."
The team identified many new causal candidate genes and the enhancers that regulate them, providing answers to critical questions about CL/P. In the future, the team hopes that as they delve more into the biology of specific causative genes, new preventions and therapies for a range of craniofacial conditions that include CL/P, can be developed.
This work was funded by grants from the National Institutes of Health (R01 CA078831, F31 GM123744-01, F32 12461842, R15GM128049), the German Research Council, and the German Research Foundation.
Coauthors on the study are Yemin Lan, Julia Welzenbach, Katherine A. Alexander, Zhen Zhang, and Morgan Sammons, all from Penn, as well as Michael Knapp, Elisabeth Mangold, and Kerstin U. Ludwig, from the University of Bonn, Germany.
Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania(founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $7.8 billion enterprise.
The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $425 million awarded in the 2018 fiscal year.
The University of Pennsylvania Health System's patient care facilities include: the Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center--which are recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report--Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; and Pennsylvania Hospital, the nation's first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Home Care and Hospice Services, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is powered by a talented and dedicated workforce of more than 40,000 people. The organization also has alliances with top community health systems across both Southeastern Pennsylvania and Southern New Jersey, creating more options for patients no matter where they live.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2018, Penn Medicine provided more than $525 million to benefit our community.